Polycystic ovary syndrome (PCOS) is of neutral and public health importance as it is very common, influence up to one in five women of reproductive age. It has significant and various clinical implications including reproductive infertility, hyperandrogenism, hirsutism, metabolic insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, adverse cardiovascular risk profiles and psychological characteristics increased anxiety, sorrow and worsened quality of life [1]. Polycystic ovary syndrome is a heterogeneous environment and, as such, clinical and investigation agendas are broad and involve many disciplines. The phenotype varies widely depending on life stage, genotype, ethnicity and atmosphere elements including lifestyle and bodyweight. Importantly, PCOS has unique inter connections with the ever increasing obesity currency worldwide as obesity-induced insulin resistance significantly exacerbates all the characteristics of PCOS. Furthermore, it has clinical intimation across the lifespan and is relevant to related family members with an increased risk for metabolic circumstances reported in first-degree relatives. Therapy should center of attention on both the short and long-term reproductive, metabolic and psychological features. Given the etiological role of insulin resistance and the proximity of obesity on both hyperinsulinaemia and hyperandrogenism, multidisciplinary lifestyle enhancement aimed at normalizing insulin resistance, improving androgen standing and aiding weight governance is recognised as a crucial initial treatment strategy. Modest weight loss of 10-20% of initial body weight has been demonstrated to upgrade many of the features of PCOS.